Effects of Immunosuppressants on Cell Metabolism

免疫抑制剂对细胞代谢的影响

• 批准号: 6896745
• 负责人: UWE CHRISTIANS
• 金额: $ 29.62万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-15 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6896745
• 关键词: bioenergetics; calcineurin; drug interactions; drug screening /evaluation; enzyme activity; esterase inhibitor; histology; kidney pharmacology; kidney transplantation; laboratory rat; magnetic resonance imaging; mitochondrial disease /disorder; peptidylprolyl isomerase; pharmacokinetics; protein structure function; renal ischemia /hypoxia; renal toxin; reperfusion; sirolimus; transplantation immunology; vascular endothelium; vasoconstriction

DESCRIPTION (provided by applicant): The calcineurin inhibitors, (CIs) cyclosporinen, and tacrolimus are the basis of most immunosuppressive protocols after organ transplantation. The propensity of these agents to ultimately damage the very organs they were intended to protect, especially the kidney, was always recognized, but largely tolerated due to their impressive ability to improve short-term outcomes. With the target-of-rapamycin (TOR) inhibitor sirolimus, an equally potent immunosuppressant that itself is lacking the most important side effects of Cls, such as nephrotoxicity and neurotoxicity, has become available. The combination of sirolimus with CIs is attractive since it results in synergistic immunosuppressive activity. Although devoid of nephrotoxicity when administered alone, sirolimus unexpectedly enhanced cyclosporine nephrotoxicity in clinical studies. The exact biochemical mechanisms underlying immunosuppressant toxicity alone and in combination is still poorly understood. Based on our previous work, we hypothesize that both, CI-induced mitochondrial dysfunction in blood vessel endothelium leading to vasoconstriction and direct negative effects on mitochondrial kidney energy metabolism, cause CI nephrotoxicity and that TOR inhibitors enhance CI nephrotoxicity by enhancing the negative effects of CIs on mitochondrial energy metabolism. To test our hypothesis, we propose to systematically study the effect of calcineurin inhibitors and/or sirolimus on kidney and arterial endothelial cell metabolism in the rat in vivo using magnetic resonance spectroscopy (MRS) and to correlate those with histological, functional and molecular changes known to be typical for CI nephrotoxicity. We will identify the biochemical mechanisms using MRS, will evaluate the role of cyclophilin and calcineurin in the observed changes, will compare different in vivo kidney toxicity models, will evaluate the contribution of pharmacodynamic and pharmacokinetic drug interactions when calcineurin and TOR inhibitors are combined and will evaluate differences in the negative effects of the study drugs and their combinations on transplant kidneys (exposed to ischemia/reperfusion) versus non-transplant kidneys. The results of our studies (a) will give important new insights in the biochemical mechanisms underlying toxicity of immunosuppressants and their combinations, (b) will identify surrogate markers for immunosuppressant toxicity (e.g. the potential use of isoprostanes for clinical pharmacodynamic monitoring of CI toxicity) and (c) will propose assays to test interactions of immunosuppressants in terms of toxicity during pre-clinical development.

描述（由申请人提供）：钙调神经磷酸酶抑制剂（CI）环孢菌素和他克莫司是器官移植后大多数免疫抑制方案的基础。 这些药物最终损害其旨在保护的器官（尤其是肾脏）的倾向一直被认可，但由于其改善短期结局的能力令人印象深刻，因此在很大程度上被耐受。 随着雷帕霉素靶向（TOR）抑制剂西罗莫司，一种同样有效的免疫抑制剂，其本身缺乏最重要的副作用，如肾毒性和神经毒性，已成为可用的。 西罗莫司与CI的组合是有吸引力的，因为它产生协同免疫抑制活性。 尽管单独给药时没有肾毒性，但西罗莫司在临床研究中出乎意料地增强了环孢素的肾毒性。 免疫抑制剂单独和联合毒性的确切生化机制仍然知之甚少。 基于我们以前的工作，我们假设CI诱导的血管内皮线粒体功能障碍导致血管收缩和对线粒体肾脏能量代谢的直接负面影响导致CI肾毒性，并且TOR抑制剂通过增强CI对线粒体能量代谢的负面影响来增强CI肾毒性。 为了验证我们的假设，我们建议系统地研究钙调磷酸酶抑制剂和/或西罗莫司对肾脏和动脉内皮细胞代谢的影响，在大鼠体内使用磁共振波谱（MRS）和相关的组织学，功能和分子的变化是典型的CI肾毒性。 我们将使用MRS确定生化机制，将评价亲环蛋白和钙调神经磷酸酶在观察到的变化中的作用，将比较不同的体内肾毒性模型，将评价钙调磷酸酶和TOR抑制剂联合用药时药效学和药代动力学药物相互作用的贡献，并将评价研究药物及其联合用药对移植肾的不良影响差异（暴露于缺血/再灌注）对比非移植肾。我们的研究结果（a）将为免疫抑制剂及其组合的潜在毒性的生化机制提供重要的新见解，（B）将鉴定免疫抑制剂毒性的替代标志物（例如，异前列烷用于CI毒性的临床药效学监测的潜在用途）和（c）将提出在临床前开发期间测试免疫抑制剂在毒性方面的相互作用的测定。